FindTrial
Sign In

Benefit and Harm of Angiotensin Converting Enzyme Inhibitor and Angiotensin Receptor Blocker in COVID-19 Patients: A Review Protocol of Systematic Review and Meta-Analysis

Benefit and Harm of Angiotensin Converting Enzyme Inhibitor and Angiotensin Receptor Blocker in COVID-19 Patients: A Review Protocol of Systematic Review and Meta-Analysis - Benefit and Harm of Angiotensin Converting Enzyme Inhibitor and Angiotensin Receptor Blocker in COVID-19 Patients: A Review Protocol of Systematic Review and Meta-Analysis

Status
Recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000041430
Enrollment
Unknown
Registered
2020-08-16
Start date
2020-07-30
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

There is a controversial debate regarding how to treat cardiovascular disease in COVID-19 confirmed patients. Ones documented that ACE inhibitor may increase risk of fatal COVID-19 by serving entry site for this virus, on contrary ones documented that ACEi and/or ARB may be beneficial for Acute Lung Injury and cardiovascular protection.

Interventions

None listed

Sponsors

Faculty of Medicine, Universitas Airlangga
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: We will include retrospective clinical study that assessed the effect of ACEi-ARB treatment for COVID-19 patient.

Exclusion criteria

Exclusion criteria: The exclusion criteria are (1) non-English articles; (2) review, case-control studies, case reports, and case series; (3) studies without full-text articles; (4) studies that do not contain primary data in their published articles; and (5) unpublished records such as conference papers, theses, and patents.

Design outcomes

Primary

MeasureTime frame
cardiovascular mortality, all-cause mortality, severity, ARDS, need for ICU care, mechanical ventilation, hospitalization, cardiovascular injury, myocarditis, myocardial infarction, stroke, and heart failure—

Secondary

MeasureTime frame
individual percentage of primary outcomes—

Countries

Asia(except Japan)

Contacts

Public ContactEka Utami

Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya Department of Cardiology and Vascular Medicine

eka.rahayu.utami@gmail.com6287701500013

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026